Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Haoyuan Chemexpress CoSHSE:688131 +3.19%86 Net Current Asset Value is ¥3.44 as of Mar. 2026, which is 100% below its 10-year median of 17.37. GuruFocus rates SHSE:688131 with a GF Score™ of 86/100 and a GF Value™ of ¥66.97 (Significantly Overvalued). The stock has 11 warning signs investors should review. Among 605 Drug Manufacturers companies, Shanghai Haoyuan Chemexpress Co ranks worse than 88.43% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Shanghai Haoyuan Chemexpress Co's Net Current Asset Value or its related term are showing as below:
SHSE:688131'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.46 Med: 17.37 Max: 29.1
Current: 29.1
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Shanghai Haoyuan Chemexpress Co was 29.10. The lowest was 8.46. And the median was 17.37.
SHSE:688131's Price-to-Net-Current-Asset-Value is ranked worse than 88.43% of 605
companies
in the Drug Manufacturers industry
Industry Median: 6.07
vs SHSE:688131: 29.10
Shanghai Haoyuan Chemexpress Co (SHSE:688131) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Shanghai Haoyuan Chemexpress Co Net Current Asset Value Related Terms
Shanghai Haoyuan Chemexpress Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haoyuan Chemexpress Co Net Current Asset Value Chart
SHSE:688131 vs ZTS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Haoyuan Chemexpress Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haoyuan Chemexpress Co Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Haoyuan Chemexpress Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Shanghai Haoyuan Chemexpress Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ¥3.44 mean?
Shanghai Haoyuan Chemexpress Co (SHSE:688131) has a Net Current Asset Value of ¥3.44 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shanghai Haoyuan Chemexpress Co and its competitors. This is 80% below median its historical median of 17.37. Over the past decade, Shanghai Haoyuan Chemexpress Co's Net Current Asset Value has ranged from 8.46 to 29.10. According to the industry distribution chart, Shanghai Haoyuan Chemexpress Co ranks #535 out of 605 companies in the Drug Manufacturers industry, placing it in the top 88.4%.
Is Shanghai Haoyuan Chemexpress Co's Net Current Asset Value too high?
Shanghai Haoyuan Chemexpress Co's current Net Current Asset Value of ¥3.44 is 80% below median its 10-year median of 17.37. Over the past 10 years, this metric has ranged from a low of 8.46 to a high of 29.10. Based on the distribution chart, Shanghai Haoyuan Chemexpress Co ranks #535 out of 605 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Haoyuan Chemexpress Co has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haoyuan Chemexpress Co's Net Current Asset Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Haoyuan Chemexpress Co ranks #535 out of 605 companies for Net Current Asset Value. This places Shanghai Haoyuan Chemexpress Co in the lower half of its industry. The industry median Net Current Asset Value is 6.07. Historically, Shanghai Haoyuan Chemexpress Co's own Net Current Asset Value has ranged from 8.46 to 29.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 6.07, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shanghai Haoyuan Chemexpress Co and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 6.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haoyuan Chemexpress Co's current Net Current Asset Value is ¥3.44, which is 80% below median its own 10-year median of 17.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haoyuan Chemexpress Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co (SHSE:688131) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥66.97, compared to a current price of ¥100.09 — trading 49.5% above its estimated fair value. The current Net Current Asset Value is ¥3.44, which is 80% below median its 10-year median of 17.37. Shanghai Haoyuan Chemexpress Co's overall GF Score™ is 86/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Shanghai Haoyuan Chemexpress Co (SHSE:688131), the current Net Current Asset Value is ¥3.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haoyuan Chemexpress Co (SHSE:688131) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co stock appears to be overvalued.
The current stock price of ¥100.09 is trading 49.5% above its estimated GF Value™ of ¥66.97.
GuruFocus considers Shanghai Haoyuan Chemexpress Co to be Significantly Overvalued.
Key valuation signals for SHSE:688131:
Net Current Asset Value: ¥3.44 (80% below median its 10-year median of 17.37)
GF Value™: ¥66.97 vs. price of ¥100.09 (49.5% above fair value)
No single metric tells the full story. See the SHSE:688131 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haoyuan Chemexpress Co Ltd focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. The company's comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. It is a one-stop service platform to support client's projects from early drug discovery, process development to commercialization. The company is committed to delivering high-quality products and CMC services to clients across the entire life cycle of drug development.
86GF Score
Get the complete analysis for SHSE:688131
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688131 has been successfully added to your 
